As a global leading contract development and manufacturing organization (CDMO) for cell and gene therapy products, Minaris Regenerative Medicine has been offering our clients high value clinical and commercial manufacturing services, development solutions, and technologies for more than 20 years.
As a global company with facilities in the U.S., Germany, and Japan, we will be shifting to a model of regional operational leadership beginning October 1, 2021. The three regional Chief Operating Officers will collaborate on a Global Functional team. Please read our press release to learn more about those appointed.
Wondering where your patient-specific cell therapy product stands on the path to commercial readiness? Our team of experts created a checklist to help you assess your therapeutic candidate.
